BofA Reaffirms Buy Rating for Agios Pharmaceuticals (AGIO)

On April 21, BofA expert Alec Stranahan reduced the terms people connected Agios Pharmaceuticals Inc. (NASDAQ:AGIO) to $41 from $44, portion maintaining a Buy standing connected the stock. Stranahan highlighted that Agios intends to question accelerated support and has already filed a connection for a confirmatory proceedings with an updated superior endpoint.

Tonhom1009/Shutterstock.com

Nevertheless, the expert noted that topline results of the HIBISCUS survey of Novo Nordisk’s etavopivat for sickle compartment illness volition airs a regulatory hazard for Agios’ mitapivat. Despite specified competitory risks, the banal is inactive amongst the champion oversold small-cap names close now.

On April 20, H.C. Wainwright expert Emily Bodnar reduced the terms people connected Agios Pharmaceuticals Inc. (NASDAQ:AGIO) from $65 to $50, portion maintaining a Buy standing connected the stock. She attributed this downward revision to Novo Nordisk’s HIBISCUS Phase 3 trial, noting that some superior endpoints were met, which is definite to effect successful occurrence for sickle compartment disease.

Novo’s etavopivat is taken erstwhile a time compared to Agios’ mitapivat taken doubly a day. Given that Novo offers aggregate medications for preventing hemorrhages successful hemophilia A/B patients, the institution expects to unafraid a ample marketplace share, according to the analyst. The HIBISCUS information is expected to trim the commercialization imaginable of mitapivat.

Agios Pharmaceuticals Inc. (NASDAQ:AGIO) is engaged successful discovering and creating therapeutics successful the tract of cellular metabolism successful the United States. It offers a scope of drugs for antithetic illnesses. Its merchandise offering includes PYRUKYND (mitapivat), AQVESME, tebapivat, AG-181, and AG-236.

While we admit the imaginable of AGIO arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double successful 3 Years and 15 Stocks That Will Make You Rich successful 10 Years.

Disclosure: None. Follow Insider Monkey connected Google News.